Free

Learning from suramin: A case study of NCI’s much-hyped cancer drug that crashed and burned—35 years ago
FreeGuest Editorial

Learning from suramin: A case study of NCI’s much-hyped cancer drug that crashed and burned—35 years ago

Almost 35 years ago, while the nation suffered in the vicious grip of the HIV epidemic, a young man from South Carolina with AIDS named Boyd Helton found his way to the NIH Clinical Center in Bethesda. While there, he was recruited into a clinical research protocol designed to lower the expression of viral proteins in his blood, and, ideally, to increase the numbers of his circulating CD4+ T-cells.
FreeFunding Opportunities

Why cancer innovation must go beyond medicine:
The C3 Prize search for ideas with the greatest potential for impact

I have devoted my career to improving care for people living with cancer. It wasn't until my father was diagnosed with head and neck cancer that I realized just how complex navigating the cancer care experience can be—and how much I had to learn as a caregiver. To improve the lives of people living with cancer, we must focus on more than treatment and address care holistically.